Skye Bioscience, Inc. (OTCQB: SKYE), a pharmaceutical company developing a proprietary, synthetic cannabinoid derivative to treat glaucoma, reported that the human research ethics committee in Australia has approved the initiation of the multiple ascending dose ("MAD") arm of Skye's phase 1 study of SBI-100 ophthalmic emulsion. Skye expects to dose the first MAD cohort in April.
In a similar fashion to the single ascending dose arm, each of the three MAD cohorts will consist of eight healthy participants, six to be randomized to SBI-100 OE and two randomized to placebo. Participants receiving SBI-100 OE will receive drug concentrations of 0.5%, 1.0%, and 2.0% per respective cohort. Each participant in the MAD arm will be administered a topical dose of SBI-100 OE or …